Essilor® proudly unveils the Essilor® Stellest® 2.0 lens, powered by advanced Highly Aspherical Lenslet Target (H.A.L.T.*) MAX technology. Designed with increased lenslet power and asphericity, this next-generation lens builds on the original H.A.L.T.* technology first launched in 2020.

Validated in a one-year clinical crossover study, Essilor® Stellest® 2.0 lenses have demonstrated significantly greater efficacy in slowing myopic eye growth compared to the first-generation lenses.1,2

Millions of children around the world have already benefited from the first-generation Essilor® Stellest® lenses, which have been shown to slow down myopia progression by 67% on average.†3 Essilor® Stellest® 2.0 lenses, powered by H.A.L.T.* MAX technology, provide twice the signal,‡ slowing myopic eye growth even further compared to the first-generation lens.§ 1,2

Charlotte Timbury, Director of Medical & Professional Affairs for EssilorLuxottica North Europe, said: “As long as childhood myopia continues, Essilor® will never stop searching for new ways to manage it, and this innovation is our most efficacious solution for myopia management yet.”

Wearers will continue to enjoy the same trusted benefits of Essilor® Stellest® lenses - clear, corrected vision without compromising aesthetics and safety¶ - but with added power, # and efficacy§1,2 making it an ideal choice for children with early onset myopia.

TECHNOLOGICAL ADVANCES  
Essilor's continued research in myopia has led to this new advancement. R&D experts identified a dose-dependent relationship between the characteristics of the lenslets and myopia progression control efficacy, enabling them to hypothesise an optimal “dosage” of lenslet power and asphericity, which was then incorporated into the new lens design.

Charlotte Timbury, said: “The lenslets work on two key principles: increasing the mean power and increasing the asphericity of the lenslets. Together, these changes provide twice the depth of volume of non-focused light positioned further from the retina, compared to the previous generation lens.‡ This results in a stronger optical signal that can help slow axial elongation.”  

The lenslets in Essilor® Stellest® 2.0 lenses are spread over 12 rings on the lens, as opposed to 11 in the previous generation, and the lens is also available up to a wider 75mm diameter, allowing for a broader frame choice.

CLINICAL TRIAL
To assess the efficacy of Essilor® Stellest® 2.0 lenses, a contralateral crossover clinical trial was conducted in Singapore with 50 children.

The results showed that Essilor® Stellest® 2.0 lenses, powered by H.A.L.T.* MAX technology, significantly slowed axial elongation compared to Essilor® Stellest® lenses with H.A.L.T.* technology at month 6 and 12.1,2 In fact, with Essilor® Stellest® 2.0 lenses, eye growth in myopic children was 1.88 times slower than with Essilor® Stellest® lenses. §1

Additionally, results indicated that younger children (aged ?8.5 years) may particularly benefit in terms of slowing axial elongation.1